2-((5-chloro-2-((5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide | 1564256-32-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 2-((5-chloro-2-((5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide
• 英文别名: 2-[[5-chloro-2-[(5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]-N-methylbenzamide
• CAS: 1564256-32-1
• 化学式: C₂₃H₂₅ClN₆O
• 分子量: 436.944
• InChiKey: AKBLFCHEFXTDBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  91
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-((2,5-二氯嘧啶-4-基)氨基)-N-甲基苯甲酰胺 、 5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-amine 在 D(+)-10-樟脑磺酸 作用下， 以 异丙醇 为溶剂， 反应 1.0h， 以48.5%的产率得到2-((5-chloro-2-((5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide
  参考文献：
  名称：

  Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities

  摘要：

  By repurposing a typical dopamine D-1/D-5 receptor agonist motif, C1-substituted-N3-benzazepine or benzazecine, into the classical RTK inhibitor 2,4-diaminopyrimidine skeleton, a series of new 2,4-diarylaminopyrimidine analogues (DAAPalogues) were developed. Compounds 7 and 8a were identified possessing high potency against both c-Met and ALK kinases. Compound 8a displayed appreciable antitumor efficacy at the dose of 1 mg/kg in the ALK-driven BF3/EML4-ALK xenograft mice model.

  DOI：

  10.1021/ml400373j

文献信息

• Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities
  作者：Zhiqing Liu、Jing Ai、Xia Peng、Zilan Song、Kui Wu、Jing Zhang、Qizheng Yao、Yi Chen、Yinchun Ji、Yanhong Yang、Meiyu Geng、Ao Zhang

  DOI：10.1021/ml400373j

  日期：2014.4.10

  By repurposing a typical dopamine D-1/D-5 receptor agonist motif, C1-substituted-N3-benzazepine or benzazecine, into the classical RTK inhibitor 2,4-diaminopyrimidine skeleton, a series of new 2,4-diarylaminopyrimidine analogues (DAAPalogues) were developed. Compounds 7 and 8a were identified possessing high potency against both c-Met and ALK kinases. Compound 8a displayed appreciable antitumor efficacy at the dose of 1 mg/kg in the ALK-driven BF3/EML4-ALK xenograft mice model.